Orion Genomics To Use Genomics Collaborative's Tissue Samples For Cancer Biomarker Discovery
5/4/2006 4:52:36 PM
NEW YORK, May 4 (GenomeWeb News) - Genomics Collaborative, a division of SeraCare Life Sciences, said today that it will provide Orion Genomics with annotated clinical tumor tissue specimens for use in Orion's cancer biomarker discovery and validation program. Orion Genomics, a developer of DNA-methylation-based molecular diagnostics, will screen the tissue samples to discover and validate epigenetic biomarkers that are indicative of the presence and stage of disease, Genomics Collaborative said. The deal is the second procurement agreement between the two firms. Additional terms were not disclosed.